CATB Catabasis Pharmaceuticals Inc.

4.67
-0.14  -3%
Previous Close 4.81
Open 4.76
Price To Book 1.25
Market Cap 54,251,913
Shares 11,617,112
Volume 110,844
Short Ratio
Av. Daily Volume 83,604
Stock charts supplied by TradingView

NewsSee all news

  1. Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by

  2. Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

    -- Differentiating Safety and Tolerability Profile of Edasalonexent Through More Than 55 Patient Years of Exposure -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today

  3. Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

    -- Top-line Results Expected Fourth Quarter of 2020 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD

  4. Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular

  5. Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

    -- Edasalonexent Inhibits NF-kB, a Potential Driver of Disease Progression in Dysferlinopathy -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and the Jain Foundation, a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 4Q 2020.
Edasalonexent (CAT-1004)
Duchenne muscular dystrophy (DMD)
Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia

Latest News

  1. Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by

  2. Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

    -- Differentiating Safety and Tolerability Profile of Edasalonexent Through More Than 55 Patient Years of Exposure -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today

  3. Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

    -- Top-line Results Expected Fourth Quarter of 2020 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD

  4. Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular

  5. Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

    -- Edasalonexent Inhibits NF-kB, a Potential Driver of Disease Progression in Dysferlinopathy -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and the Jain Foundation, a

  6. Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer

    Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer. Mr. Komjathy brings to Catabasis more than 30